Sudden Sensorineural Hearing Loss Clinical Trial
Official title:
Small Sample,Unicentric,Randomized, Controlled Clinical Study of Coenzyme I for Injection in the Treatment of Sudden Sensorineural Hearing Loss
Sudden sensorineural hearing loss is one of the most common emergencies in otorhinolaryngology, and its incidence is increasing year by year and tends to be younger. At present, the pathogenesis of sudden deafness is not clear and the individual treatment effects vary significantly. In order to break through this specific treatment bottleneck, this project pioneered the clinical application of the co-regulator nicotinamide adenine dinucleotide (NAD+) in the treatment of sudden deafness. Therefore, this project intends to use pure tone audiometry, speech audiometry, tinnitus disability scale THI, tinnitus subjective visual analog score method VAS, ear fullness subjective visual analog score method VAS for data analysis, and explore the safety of coenzyme I for injection on sudden deafness and efficacy assessment.
Status | Recruiting |
Enrollment | 36 |
Est. completion date | February 16, 2024 |
Est. primary completion date | February 16, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Age =18yrs.the 2019 American Sudden Deafness Guidelines are for patients with sudden deafness over 18 years of age; 2. Patients diagnosed with sudden deafness, i.e. unexplained sensorineural hearing loss occurring within 72 hours, with hearing threshold =30 in at least 3 consecutive frequencies, refer to the 2019 American Sudden Deafness Guidelines; 3. Unilateral sudden deafness; 4. Within 1 week of the onset of sudden deafness, no treatment in another hospital/our hospital; 5. No major neurological disease, serious systemic disease, family genetic history, major mental illness; 6. Informed and agreed to join the experiment, no plan to move out or go out within 1 month. Exclusion Criteria: 1. Other diseases such as acoustic neuroma diagnosed by imaging; 2. Those who cannot tolerate NAD+; 3. pregnant; 4. Any other circumstances that the investigator believes should be excluded from this study; 5. Do not agree to join the experiment, plan to move out or go out within 1 month. |
Country | Name | City | State |
---|---|---|---|
China | Sun Yat-sen Memorial Hospital of Sun Yat-sen University | Guangzhou | Guangdong |
Lead Sponsor | Collaborator |
---|---|
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Pure Tone Average(PTA) | Pure tone audiometry is the most basic and preferred hearing test method, which can qualitatively and quantitatively diagnose hearing loss, can reflect the entire auditory conduction pathway from the external ear to the auditory center, and is currently one of the subjective behavioral hearing tests that can accurately reflect hearing acuity. Includes pure tone air conduction hearing threshold test and pure tone bone hearing threshold test. | Baseline, before treatment | |
Primary | Pure Tone Average(PTA) | Pure tone audiometry is the most basic and preferred hearing test method, which can qualitatively and quantitatively diagnose hearing loss, can reflect the entire auditory conduction pathway from the external ear to the auditory center, and is currently one of the subjective behavioral hearing tests that can accurately reflect hearing acuity. Includes pure tone air conduction hearing threshold test and pure tone bone hearing threshold test. | Treatment day 3 | |
Primary | Pure Tone Average(PTA) | Pure tone audiometry is the most basic and preferred hearing test method, which can qualitatively and quantitatively diagnose hearing loss, can reflect the entire auditory conduction pathway from the external ear to the auditory center, and is currently one of the subjective behavioral hearing tests that can accurately reflect hearing acuity. Includes pure tone air conduction hearing threshold test and pure tone bone hearing threshold test. | Treatment day 7 | |
Primary | Pure Tone Average(PTA) | Pure tone audiometry is the most basic and preferred hearing test method, which can qualitatively and quantitatively diagnose hearing loss, can reflect the entire auditory conduction pathway from the external ear to the auditory center, and is currently one of the subjective behavioral hearing tests that can accurately reflect hearing acuity. Includes pure tone air conduction hearing threshold test and pure tone bone hearing threshold test. | Treatment day 14 | |
Primary | Pure Tone Average(PTA) | Pure tone audiometry is the most basic and preferred hearing test method, which can qualitatively and quantitatively diagnose hearing loss, can reflect the entire auditory conduction pathway from the external ear to the auditory center, and is currently one of the subjective behavioral hearing tests that can accurately reflect hearing acuity. Includes pure tone air conduction hearing threshold test and pure tone bone hearing threshold test. | Treatment day 30 | |
Primary | Pure Tone Average(PTA) | Pure tone audiometry is the most basic and preferred hearing test method, which can qualitatively and quantitatively diagnose hearing loss, can reflect the entire auditory conduction pathway from the external ear to the auditory center, and is currently one of the subjective behavioral hearing tests that can accurately reflect hearing acuity. Includes pure tone air conduction hearing threshold test and pure tone bone hearing threshold test. | Treatment day 90 | |
Secondary | Speech Recognition Rate | The speech recognition rate is the percentage (%) of speech which can be heard correctly in the audiometric vocabulary list, and the curve is drawn according to the (%) understood by different sound intensity levels, that is, the speech audiogram. | Baseline, before treatment | |
Secondary | Speech Recognition Rate | The speech recognition rate is the percentage (%) of speech which can be heard correctly in the audiometric vocabulary list, and the curve is drawn according to the (%) understood by different sound intensity levels, that is, the speech audiogram. | Treatment day 3 | |
Secondary | Speech Recognition Rate | The speech recognition rate is the percentage (%) of speech which can be heard correctly in the audiometric vocabulary list, and the curve is drawn according to the (%) understood by different sound intensity levels, that is, the speech audiogram. | Treatment day 7 | |
Secondary | Speech Recognition Rate | The speech recognition rate is the percentage (%) of speech which can be heard correctly in the audiometric vocabulary list, and the curve is drawn according to the (%) understood by different sound intensity levels, that is, the speech audiogram. | Treatment day 14 | |
Secondary | Speech Recognition Rate | The speech recognition rate is the percentage (%) of speech which can be heard correctly in the audiometric vocabulary list, and the curve is drawn according to the (%) understood by different sound intensity levels, that is, the speech audiogram. | Treatment day 30 | |
Secondary | Speech Recognition Rate | The speech recognition rate is the percentage (%) of speech which can be heard correctly in the audiometric vocabulary list, and the curve is drawn according to the (%) understood by different sound intensity levels, that is, the speech audiogram. | Treatment day 90 | |
Secondary | Tinnitus Handicap Inventory | The Tinnitus Handicap Inventory (THI) is a tool to measure the impact of tinnitus on daily life.
Yes (always has): 4 points; Sometimes (intermittent presence): 2 points.None: 0 points; None:0 points. Divide tinnitus into grade 5 I (mild), THI score 1~16 divide; Grade 2 (mild), THI score 18~36 points; Level 3 (moderate), THI score 38~56 points; Level 4 (severe), THI score 58~76 points; Level 5 (catastrophic), THI score 78~100 points. |
Baseline, before treatment | |
Secondary | Tinnitus Handicap Inventory | The Tinnitus Handicap Inventory (THI) is a tool to measure the impact of tinnitus on daily life.
Yes (always has): 4 points; Sometimes (intermittent presence): 2 points.None: 0 points; None:0 points. Divide tinnitus into grade 5 I (mild), THI score 1~16 divide; Grade 2 (mild), THI score 18~36 points; Level 3 (moderate), THI score 38~56 points; Level 4 (severe), THI score 58~76 points; Level 5 (catastrophic), THI score 78~100 points. |
Treatment day 3 | |
Secondary | Tinnitus Handicap Inventory | The Tinnitus Handicap Inventory (THI) is a tool to measure the impact of tinnitus on daily life.
Yes (always has): 4 points; Sometimes (intermittent presence): 2 points.None: 0 points; None:0 points. Divide tinnitus into grade 5 I (mild), THI score 1~16 divide; Grade 2 (mild), THI score 18~36 points; Level 3 (moderate), THI score 38~56 points; Level 4 (severe), THI score 58~76 points; Level 5 (catastrophic), THI score 78~100 points. |
Treatment day 7 | |
Secondary | Tinnitus Handicap Inventory | The Tinnitus Handicap Inventory (THI) is a tool to measure the impact of tinnitus on daily life.
Yes (always has): 4 points; Sometimes (intermittent presence): 2 points.None: 0 points; None:0 points. Divide tinnitus into grade 5 I (mild), THI score 1~16 divide; Grade 2 (mild), THI score 18~36 points; Level 3 (moderate), THI score 38~56 points; Level 4 (severe), THI score 58~76 points; Level 5 (catastrophic), THI score 78~100 points. |
Treatment day 14 | |
Secondary | Tinnitus Handicap Inventory | The Tinnitus Handicap Inventory (THI) is a tool to measure the impact of tinnitus on daily life.
Yes (always has): 4 points; Sometimes (intermittent presence): 2 points.None: 0 points; None:0 points. Divide tinnitus into grade 5 I (mild), THI score 1~16 divide; Grade 2 (mild), THI score 18~36 points; Level 3 (moderate), THI score 38~56 points; Level 4 (severe), THI score 58~76 points; Level 5 (catastrophic), THI score 78~100 points. |
Treatment day 30 | |
Secondary | Tinnitus Handicap Inventory | The Tinnitus Handicap Inventory (THI) is a tool to measure the impact of tinnitus on daily life.
Yes (always has): 4 points; Sometimes (intermittent presence): 2 points.None: 0 points; None:0 points. Divide tinnitus into grade 5 I (mild), THI score 1~16 divide; Grade 2 (mild), THI score 18~36 points; Level 3 (moderate), THI score 38~56 points; Level 4 (severe), THI score 58~76 points; Level 5 (catastrophic), THI score 78~100 points. |
Treatment day 90 | |
Secondary | Visual Analogue Scale of Tinnitus | VAS (Visual Analogue Scale) is a tool to detect changes in the subjective loudness of tinnitus. 0 represents no tinnitus loudness at all, 10 represents the presence of extremely severe loudness, and the middle represents different degrees of tinnitus loudness. | Baseline, before treatment | |
Secondary | Visual Analogue Scale of Tinnitus | VAS (Visual Analogue Scale) is a tool to detect changes in the subjective loudness of tinnitus. 0 represents no tinnitus loudness at all, 10 represents the presence of extremely severe loudness, and the middle represents different degrees of tinnitus loudness. | Treatment day 3 | |
Secondary | Visual Analogue Scale of Tinnitus | VAS (Visual Analogue Scale) is a tool to detect changes in the subjective loudness of tinnitus. 0 represents no tinnitus loudness at all, 10 represents the presence of extremely severe loudness, and the middle represents different degrees of tinnitus loudness. | Treatment day 7 | |
Secondary | Visual Analogue Scale of Tinnitus | VAS (Visual Analogue Scale) is a tool to detect changes in the subjective loudness of tinnitus. 0 represents no tinnitus loudness at all, 10 represents the presence of extremely severe loudness, and the middle represents different degrees of tinnitus loudness. | Treatment day 14 | |
Secondary | Visual Analogue Scale of Tinnitus | VAS (Visual Analogue Scale) is a tool to detect changes in the subjective loudness of tinnitus. 0 represents no tinnitus loudness at all, 10 represents the presence of extremely severe loudness, and the middle represents different degrees of tinnitus loudness. | Treatment day 30 | |
Secondary | Visual Analogue Scale of Tinnitus | VAS (Visual Analogue Scale) is a tool to detect changes in the subjective loudness of tinnitus. 0 represents no tinnitus loudness at all, 10 represents the presence of extremely severe loudness, and the middle represents different degrees of tinnitus loudness. | Treatment day 90 | |
Secondary | Severity of ear fullness | Visual Analogue Scale(VAS).0 represents no ear stuffiness at all, 10 represents the presence of extremely severe ear stuffiness, and the middle represents different degrees of ear stuffiness. | Baseline, before treatment | |
Secondary | Severity of ear fullness | Visual Analogue Scale(VAS).0 represents no ear stuffiness at all, 10 represents the presence of extremely severe ear stuffiness, and the middle represents different degrees of ear stuffiness. | Treatment day 3 | |
Secondary | Severity of ear fullness | Visual Analogue Scale(VAS).0 represents no ear stuffiness at all, 10 represents the presence of extremely severe ear stuffiness, and the middle represents different degrees of ear stuffiness. | Treatment day 7 | |
Secondary | Severity of ear fullness | Visual Analogue Scale(VAS).0 represents no ear stuffiness at all, 10 represents the presence of extremely severe ear stuffiness, and the middle represents different degrees of ear stuffiness. | Treatment day 14 | |
Secondary | Severity of ear fullness | Visual Analogue Scale(VAS).0 represents no ear stuffiness at all, 10 represents the presence of extremely severe ear stuffiness, and the middle represents different degrees of ear stuffiness. | Treatment day 30 | |
Secondary | Severity of ear fullness | Visual Analogue Scale(VAS).0 represents no ear stuffiness at all, 10 represents the presence of extremely severe ear stuffiness, and the middle represents different degrees of ear stuffiness. | Treatment day 90 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04120116 -
FX-322 in Adults With Stable Sensorineural Hearing Loss
|
Phase 2 | |
Recruiting |
NCT05403229 -
The Role of Migraine Prophylaxis Agent Topiramate in Treating Patients With Sudden Sensorineural Hearing Loss
|
Phase 2 | |
Not yet recruiting |
NCT05608161 -
Speech Perception Impairment Follow Complete Recovery of Sudden Sensorineural Hearing Loss
|
||
Recruiting |
NCT04961099 -
Phase I Clinical Study of HY01 in Patients
|
Phase 1 | |
Recruiting |
NCT06278129 -
Evaluation of the Diagnostic and Prognostic Efficacy of MRI in Acute Sensorineural Hearing Loss and Ménière's Disease
|
||
Recruiting |
NCT06249919 -
A Phase 1b/2a, Study Evaluating the Safety, PK/PD and Efficacy of NS101 in Healthy Volunteers and SSNHL Patients
|
Phase 1/Phase 2 | |
Recruiting |
NCT04826237 -
Oral Statins and Protection From Hearing Loss
|
Phase 4 | |
Not yet recruiting |
NCT04224909 -
Video HIT in Sudden Sensorineural Hearing Loss
|
||
Not yet recruiting |
NCT06365775 -
Multi-omics Characteristics and Prognosis of Idiopathic Sudden Sensorineural Hearing Loss
|
||
Not yet recruiting |
NCT06355102 -
The Development of Tinnitus in Patients With SSNHL: Insights From fMRI and Metabolomics
|